Successful treatment with Harvoni in an ADA-SCID infant with HCV infection allowed gene therapy with Strimvelis.

HEPATOLOGY(2018)

引用 11|浏览15
暂无评分
摘要
Patients with inborn error diseases can be candidates for autologous haematopoietic stem cells (HSC) gene therapies (GT) but may require negative viral screening, including Hepatitis C (HCV), to allow HSC manipulation in Good Manufacturing Practices areas. In case of HCV positivity, patients might be excluded from life-saving treatments. As HCV antibodies could be negative in young infant immunodeficient patients due to their immature/impaired immune system, or positive due to maternal-fetal antibody transmission, the risk is usually also evaluated on the basis of the HCV-RNA. This article is protected by copyright. All rights reserved.
更多
查看译文
关键词
HCV-RNA,Sofosbuvir/Ledipasvir,adenosine deaminase,autologous hematopoietic stem cell transplantation,children
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要